Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma

Affiliations

¹ Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel. Electronic address: tomermrsn@gmail.com.
² Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.
³ Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁴ Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Comment

Tomer Meirson et al. Lancet Oncol. 2022 Nov.

. 2022 Nov;23(11):e489.

doi: 10.1016/S1470-2045(22)00629-5.

¹ Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel. Electronic address: tomermrsn@gmail.com.
² Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.
³ Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁴ Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

No abstract available

Comment in

Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma - Authors' reply.
Powles T, Burgents JE, Xu L, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2023 Jan;24(1):e1-e2. doi: 10.1016/S1470-2045(22)00740-9. Lancet Oncol. 2023. PMID: 36603921 No abstract available.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Clinical Trial.